Vaxcyte PCVX 深 沪
等待开盘 12-15 09:30:00 美东时间
44.50
-0.090
-0.20%
华盛通- 最 高44.925
- 今 开44.80
- 成交量 171.62万股
- 最 低 43.52
- 昨 收 44.59
- 总市值 58.30亿
- 52周最高 93.77
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 27.66
- 委 比 38.37%
- 总股本 1.31亿
- 历史最高 121.055
- 量 比 1.47
- 振 幅 3.15%
- 历史最低 15.51
- 每 手 1
- 风险率 21.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA承诺实施新疫苗要求，莫德纳股价下跌
美国食品药品监督管理局（FDA）在上周末的一份备忘录中表示，将对获批上市的疫苗实施新限制措施，受此影响，莫德纳公司（Moderna Inc．）股价于周一下跌...
12-01 23:50
CleanSpark, Cipher Mining, Bitdeer Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
12-01 21:43
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
BTIG Reiterates Buy on Vaxcyte, Maintains $85 Price Target
BTIG analyst Thomas Shrader reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $85 price target.
11-10 18:31
Vaxcyte GAAP EPS of -$1.56 misses by $0.25
Vaxcyte press release (PCVX): Q3 GAAP EPS of -$1.56 misses by $0.25. Ending the third quarter with $2.7 billion in cash, cash equivalents and investments. More on Vaxcyte Vaxcyte, Inc. (PCVX) Presents...
11-05 06:23
Vaxcyte Q3 EPS $(1.56) Misses $(1.30) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.30) by 19.82 percent. This is a 87.95 percent decrease over losses of $(0.83) per share from the
11-05 05:47
ClearBridge SMID Cap Growth Strategy
The ClearBridge SMID Cap Growth Strategy underperformed its Russell 2500 Growth Index benchmark during the third quarter, with the index gaining 10.7%. As such, the performance of SMID growth equitie...
10-13 23:15
Thermo Fisher Scientific prices $2.5B senior notes
Thermo Fisher Scientific (NYSE:TMO) priced an offering of $2.5B senior notes consiting of: $500M 4.200% senior notes due 2031 at the issue price of 99.874%; $750M 4.473% senior notes due 2032 at the...
10-01 13:28
Vaxcyte Signs 15-Year Agreement with Patheon
An update from Vaxcyte ( ($PCVX) ) is now available. On September 24, 2025, Vax...
09-30 21:24
Vaxcyte Enters Partnership With Thermo Fisher Scientific To Secure Additional U.S. Fill-Finish Commercial Manufacturing For Its Broad-Spectrum Pneumococcal Conjugate Vaccines Representing Up To $1B in Manufacturing And Service
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish
09-30 20:44
